Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices
Abbott (NYSE: ABT) has announced a global partnership with Medtronic to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. This collaboration aims to improve health outcomes and reduce the burden of decision-making for people with diabetes who use intensive insulin therapy.
The partnership involves developing a CGM sensor based on Abbott's advanced Libre technology, designed exclusively for Medtronic devices. This integration will enable automatic adjustments of insulin to maintain glucose levels within the desired range. The new CGM sensor will be developed by Abbott but sold by Medtronic.
This alliance marks Abbott's fourth partnership with major insulin delivery system developers, expanding choices for people worldwide to benefit from Libre technology connectivity. The collaboration targets the estimated 11 million people globally who require multiple daily insulin injections, including those with Type 1 and Type 2 diabetes.
Abbott (NYSE: ABT) ha annunciato una partnership globale con Medtronic per integrare la tecnologia di monitoraggio continuo della glicemia FreeStyle Libre di Abbott con i sistemi di somministrazione automatica di insulina (AID) e le penne per insulina intelligenti di Medtronic. Questa collaborazione ha come obiettivo quello di migliorare i risultati sanitari e ridurre il carico decisionale per le persone con diabete che utilizzano terapie insuliniche intensive.
La partnership prevede lo sviluppo di un sensore CGM basato sulla tecnologia avanzata Libre di Abbott, progettato esclusivamente per i dispositivi Medtronic. Questa integrazione consentirà regolazioni automatiche dell'insulina per mantenere i livelli di glucosio nel range desiderato. Il nuovo sensore CGM sarà sviluppato da Abbott ma venduto da Medtronic.
Questa alleanza segna la quarta partnership di Abbott con i principali sviluppatori di sistemi di somministrazione dell'insulina, espandendo le scelte per le persone in tutto il mondo che possono beneficiare della connettività della tecnologia Libre. La collaborazione mira ai 11 milioni di persone a livello globale che necessitano di più iniezioni giornaliere di insulina, comprese quelle con diabete di tipo 1 e tipo 2.
Abbott (NYSE: ABT) ha anunciado una asociación global con Medtronic para integrar la tecnología de monitoreo continuo de glucosa FreeStyle Libre de Abbott con los sistemas de suministro automático de insulina (AID) y las plumas inteligentes de insulina de Medtronic. Esta colaboración tiene como objetivo mejorar los resultados de salud y reducir la carga de toma de decisiones para las personas con diabetes que utilizan terapia intensiva de insulina.
La asociación implica el desarrollo de un sensor CGM basado en la avanzada tecnología Libre de Abbott, diseñado exclusivamente para los dispositivos de Medtronic. Esta integración permitirá ajustes automáticos de insulina para mantener los niveles de glucosa dentro del rango deseado. El nuevo sensor CGM será desarrollado por Abbott pero vendido por Medtronic.
Esta alianza marca la cuarta asociación de Abbott con importantes desarrolladores de sistemas de suministro de insulina, expandiendo las opciones para que las personas en todo el mundo se beneficien de la conectividad de la tecnología Libre. La colaboración está dirigida a los 11 millones de personas a nivel mundial que requieren inyecciones múltiples diarias de insulina, incluidas aquellas con diabetes tipo 1 y tipo 2.
애보트(뉴욕증권거래소: ABT)는 메드트로닉과의 글로벌 파트너십을 발표하여 애보트의 FreeStyle Libre 지속혈당 모니터링(CGM) 기술을 메드트로닉의 자동 인슐린 전달(AID) 및 스마트 인슐린 펜 시스템과 통합합니다. 이번 협력의 목적은 당뇨병 환자들의 건강 결과를 개선하고 의사결정의 부담을 줄이는 것입니다.
파트너십은 메드트로닉 장치 전용으로 설계된 애보트의 고급 Libre 기술 기반 CGM 센서 개발을 포함합니다. 이 통합을 통해 글ucose 수준을 원하는 범위 내에서 유지하기 위해 인슐린을 자동으로 조정할 수 있게 됩니다. 새로운 CGM 센서는 애보트에서 개발되지만 메드트로닉에서 판매됩니다.
이번 동맹은 애보트가 주요 인슐린 전달 시스템 개발자와 체결한 네 번째 파트너십으로, 전 세계 사람들이 Libre 기술의 연결성을 통해 혜택을 받을 수 있는 기회를 확대합니다. 이번 협력은 매일 여러 번 인슐린 주사가 필요한 전 세계 약 1,100만 명의 사람들, 특히 제1형 및 제2형 당뇨병 환자를 목표로 하고 있습니다.
Abbott (NYSE : ABT) a annoncé un partenariat mondial avec Medtronic pour intégrer la technologie de surveillance continue de la glycémie FreeStyle Libre d'Abbott avec les systèmes de distribution automatique d'insuline (AID) et les stylos à insuline intelligents de Medtronic. Cette collaboration vise à améliorer les résultats de santé et à réduire le fardeau de la prise de décision pour les personnes atteintes de diabète utilisant une thérapie intensive par insuline.
Le partenariat implique le développement d'un capteur CGM basé sur la technologie avancée Libre d'Abbott, conçu exclusivement pour les dispositifs Medtronic. Cette intégration permettra d'ajustements automatiques de l'insuline pour maintenir les niveaux de glucose dans la fourchette souhaitée. Le nouveau capteur CGM sera développé par Abbott mais vendu par Medtronic.
Cette alliance marque le quatrième partenariat d'Abbott avec les principaux développeurs de systèmes de distribution d'insuline, élargissant les choix pour que les personnes dans le monde entier puissent bénéficier de la connectivité de la technologie Libre. La collaboration cible les 11 millions de personnes dans le monde qui nécessitent plusieurs injections d'insuline quotidiennes, y compris celles atteintes de diabète de type 1 et de type 2.
Abbott (NYSE: ABT) hat eine globale Partnerschaft mit Medtronic angekündigt, um die kontinuierliche Glukoseüberwachungstechnologie FreeStyle Libre von Abbott mit dem automatisierten Insulinabgabesystem (AID) und den intelligenten Insulinpens von Medtronic zu integrieren. Ziel dieser Zusammenarbeit ist es, die Gesundheitsergebnisse zu verbessern und die Entscheidungsfindung für Menschen mit Diabetes, die eine intensive Insulintherapie nutzen, zu erleichtern.
Die Partnerschaft umfasst die Entwicklung eines CGM-Sensors, der auf Abbotts fortschrittlicher Libre-Technologie basiert und exklusiv für die Medtronic-Geräte konzipiert ist. Diese Integration ermöglicht es, Insulin automatisch anzupassen, um die Glukosewerte im gewünschten Bereich zu halten. Der neue CGM-Sensor wird von Abbott entwickelt, aber von Medtronic verkauft.
Diese Allianz ist die vierte Partnerschaft von Abbott mit großen Entwicklern von Insulinabgabesystemen und erweitert die Auswahlmöglichkeiten für Menschen weltweit, die von der Konnektivität der Libre-Technologie profitieren können. Die Zusammenarbeit richtet sich an die geschätzten 11 Millionen Menschen weltweit, die mehrmals täglich Insulin injizieren müssen, einschließlich derjenigen mit Typ-1- und Typ-2-Diabetes.
- Partnership with Medtronic expands Abbott's market reach in diabetes care
- Integration of Abbott's CGM with Medtronic's AID systems may improve patient outcomes
- Collaboration potentially increases Abbott's revenue through sensor sales to Medtronic
- Partnership strengthens Abbott's position in the competitive diabetes management market
- Exclusive nature of the partnership may limit Abbott's flexibility in future collaborations
- Financial terms and commercial availability timeline not disclosed, creating uncertainty for investors
This partnership between Abbott and Medtronic is a significant development in the diabetes care market. By integrating Abbott's FreeStyle Libre CGM technology with Medtronic's insulin delivery systems, they're creating a more seamless and effective solution for diabetes management. This collaboration could potentially increase Abbott's market share in the CGM space and enhance Medtronic's competitiveness in insulin delivery systems.
The partnership targets a substantial market of over 11 million people globally who require multiple daily insulin injections. This represents a significant revenue opportunity for both companies. However, the lack of disclosed financial terms and commercial availability timeline makes it challenging to quantify the immediate impact on Abbott's financials.
Investors should note that this move strengthens Abbott's position in the diabetes care market, potentially leading to long-term revenue growth and increased customer loyalty. It also demonstrates Abbott's strategy of expanding its reach through strategic partnerships, which could be a positive indicator for future growth prospects.
This partnership marks a significant step towards more integrated and automated diabetes management. The combination of Abbott's CGM technology with Medtronic's AID systems addresses a important need in diabetes care: reducing the cognitive burden on patients. This aligns with the broader trend of personalized, data-driven healthcare.
From a technological standpoint, the integration of these systems is complex and requires sophisticated algorithms. The success of this partnership will largely depend on the seamless interoperability between Abbott's sensors and Medtronic's insulin delivery devices. If executed well, this could set a new standard for integrated diabetes care solutions.
For Abbott, this partnership could drive innovation in their CGM technology, potentially leading to improvements that could benefit their entire product line. It also positions Abbott as a key player in the evolving ecosystem of connected health devices, which could open doors to future partnerships and market opportunities beyond diabetes care.
This partnership significantly alters the competitive landscape in the diabetes care market. Abbott now has partnerships with four of the largest insulin delivery system companies, solidifying its position as a dominant player in the CGM space. This strategy of wide-ranging partnerships gives Abbott a significant competitive advantage over other CGM manufacturers.
For Medtronic, this partnership addresses a key weakness in their product lineup. By integrating with Abbott's widely-used Libre technology, Medtronic can potentially improve its market position in automated insulin delivery systems. This could help Medtronic compete more effectively against other players like Tandem Diabetes Care and Insulet.
However, the non-exclusive nature of Abbott's partnerships means that the company is hedging its bets across multiple insulin delivery system manufacturers. While this reduces risk, it may also limit the depth of integration and co-development with any single partner. Investors should monitor how this strategy plays out in terms of market share and product differentiation in the long term.
- Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems
- Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology
ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.
The integration of Abbott's CGM sensor with Medtronic's AID algorithms will enable automatic adjustments of insulin to keep glucose in range. The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic.
AID systems improve health outcomes while reducing the burden of constant decision-making for people with diabetes who use intensive insulin as part of their overall therapy. AID systems can benefit people with both Type 1 and Type 2 diabetes who require multiple daily injections of rapid-acting insulin, currently estimated at more than 11 million people globally2.
Financial terms of the partnership and timing for commercial availability were not disclosed.
"This partnership pairs two global leaders in glucose sensing technology and insulin delivery," said Jared Watkin, executive vice president of Abbott's diabetes care business. "Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic's insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living."
"Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world," said Que Dallara, executive vice president and president, Medtronic Diabetes. "We're committed to simplifying diabetes management and making the transition to automated technology much more seamless for those who wish to achieve more with their diabetes care."
This collaboration with Medtronic is the latest in a series of Abbott partnerships aimed at improving and streamlining diabetes care, giving people more choices to confidently administer their insulin. Abbott's Libre single-analyte CGM technology is currently available and integrated with AID offerings from other insulin delivery companies.
About Abbott's Libre Systems
Abbott's Libre portfolio is the world's leading continuous glucose monitoring technology1, now used by more than 6 million people in more than 60 countries3. Clinical and real-world data from the millions of people that use Libre systems show that the technology helps people improve their glucose control, lower their HbA1c, decrease diabetes-related hospital admissions, and improve their quality of life4,5. The systems have partial or full reimbursement in more than 40 countries.
For important safety information, visit https://www.freestylelibre.us/safety-information.html
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
- Data on file, Abbott Diabetes Care. Based on the number of patients assigned to each manufacturer.
- Fortune Business Insights: Top Reasons Driving the Demand for Insulin Pumps, 2021
- Data on file, Abbott Diabetes Care.
- The American Journal of Managed Care, Flash CGM Associated With Event Reduction in Nonintensive Diabetes Therapy, 2021.
- American Diabetes Association, Continuous Glucose Monitors, accessed March 20, 2024.
View original content:https://www.prnewswire.com/news-releases/abbott-enters-global-partnership-to-connect-its-world-leading-continuous-glucose-monitoring-system-with-medtronics-insulin-delivery-devices-302216439.html
SOURCE Abbott
FAQ
What is the main focus of Abbott's partnership with Medtronic announced on August 7, 2024?
How will the Abbott-Medtronic partnership affect insulin delivery for diabetes patients?
What is the target market for the Abbott-Medtronic integrated diabetes management system?
How does this partnership impact Abbott's (ABT) position in the diabetes care market?
